**SUPPLEMENTARY MATERIALS
TABLE S1.** Summary of Randomized Controlled Trial Studies Analyzed

| **Study, year (ref)** | **Treatment duration** **(weeks)** | **Patient count treatment/comparator****(n)** | **Treatment** ***n* (%)** | **Comparator*****n* (%)** |
| --- | --- | --- | --- | --- |
| Gerstein, 2006 (13) | 26  | 390/405 | Insulin glargine 197 (50.5) | OADs 193 (49.5) |
| Riddle, 2003 (14) | 28  | 735/764 | Insulin glargine 355 (48.30) | NPH insulin 380 (51.7) |
| Standl, 2005 (15) | 24  | 624 | Insulin glargine + glimepiride (morning vs bedtime)624 | NA |
| Rosenstock, 2006 (16) | 24  | 216/219 | Insulin glargine 104 (48.1) | Rosiglitazone 112 (51.9) |
| Meneghini, 2010 (17) | 24/48  | 336/353 | Insulin glargine 159 (47.3) | Pioglitazone 177 (52.7) |
| Data on file, HOE-901-4021 | 24  | 209/212 | Insulin glargine 12 (53.6) | Lispro 75/25 insulin 97 (46.4) |
| Janka, 2005 (18) | 28  | 354/371 | Insulin glargine 174 (49.2) | NPH 30/70 insulin 180 (50.8) |
| Bretzel, 2008 (19) | 44  | 402/415 | Insulin glargine 198 (49.3) | Lispro insulin 204 (50.7) |
| Yki-Järvinen, 2007 (20) | 24  | 121 | Insulin glargine 121 | NA |
| Blicklé, 2009 (21) | 40  | 183/215 | Insulin glargine 100 (54.6) | Hygienic and dietary measures 83 (45.4) |
| Yki-Järvinen, 2006 (22) | 36  | 110 | Insulin glargine 61 (55.5) | NPH 49 (44.5) |

NA, not applicable; OAD, oral antihyperglycemic drugs.



